Eamonn Hobbs

Marvao Medical Devices Ltd. designs develop and markets novel medical devices. It provides products include NexSite 9Fr dual and NexSitetm 8Fr single lumen central venous catheters, as well as NexSite hemodialysis and drainage catheters. The company was founded by Christopher Davey and Mark A. Saab in 2006 and is headquartered in Dublin, Ireland.

Marvao Medical Devices Ltd. designs develop and markets novel medical devices. It provides products include NexSite 9Fr dual and NexSitetm 8Fr single lumen central venous catheters, as well as NexSite hemodialysis and drainage catheters. The company was founded by Christopher Davey and Mark A. Saab in 2006 and is headquartered in Dublin, Ireland.

ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL.

Marvao Medical Devices Ltd. designs develop and markets novel medical devices. It provides products include NexSite 9Fr dual and NexSitetm 8Fr single lumen central venous catheters, as well as NexSite hemodialysis and drainage catheters. The company was founded by Christopher Davey and Mark A. Saab in 2006 and is headquartered in Dublin, Ireland.

Marvao Medical Devices Ltd. designs develop and markets novel medical devices. It provides products include NexSite 9Fr dual and NexSitetm 8Fr single lumen central venous catheters, as well as NexSite hemodialysis and drainage catheters. The company was founded by Christopher Davey and Mark A. Saab in 2006 and is headquartered in Dublin, Ireland.

ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL.

Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020.

ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL.

Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020.

Marvao Medical Devices Ltd. designs develop and markets novel medical devices. It provides products include NexSite 9Fr dual and NexSitetm 8Fr single lumen central venous catheters, as well as NexSite hemodialysis and drainage catheters. The company was founded by Christopher Davey and Mark A. Saab in 2006 and is headquartered in Dublin, Ireland.

ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL.

Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020.

Hobbs Medical Ventures, LLC provides consulting services for the pharmaceutical industry. The private company is based in New York, NY. The company was founded by Eamonn P. Hobbs.

Marvao Medical Devices Ltd. designs develop and markets novel medical devices. It provides products include NexSite 9Fr dual and NexSitetm 8Fr single lumen central venous catheters, as well as NexSite hemodialysis and drainage catheters. The company was founded by Christopher Davey and Mark A. Saab in 2006 and is headquartered in Dublin, Ireland.

Marvao Medical Devices Ltd. designs develop and markets novel medical devices. It provides products include NexSite 9Fr dual and NexSitetm 8Fr single lumen central venous catheters, as well as NexSite hemodialysis and drainage catheters. The company was founded by Christopher Davey and Mark A. Saab in 2006 and is headquartered in Dublin, Ireland.

Harmonic Medical, Inc. develops non-invasive surgery treatment for uterine fibroids. It also treats broad range of cancer treatment such as bone metastases, metastic liver cancer, hepatocellular carcinoma, thyroid cancer, pancreatic cancer, and kidney cancer. The company is headquartered in Toronto, Canada.

Marvao Medical Devices Ltd. designs develop and markets novel medical devices. It provides products include NexSite 9Fr dual and NexSitetm 8Fr single lumen central venous catheters, as well as NexSite hemodialysis and drainage catheters. The company was founded by Christopher Davey and Mark A. Saab in 2006 and is headquartered in Dublin, Ireland.

Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020.

Marvao Medical Devices Ltd. designs develop and markets novel medical devices. It provides products include NexSite 9Fr dual and NexSitetm 8Fr single lumen central venous catheters, as well as NexSite hemodialysis and drainage catheters. The company was founded by Christopher Davey and Mark A. Saab in 2006 and is headquartered in Dublin, Ireland.